Needham & Company LLC reaffirmed their buy rating on shares of SCYNEXIS (NASDAQ:SCYX) in a research note released on Monday morning, AnalystRatings.com reports. The firm currently has a $5.00 target price on the stock.
SCYX has been the subject of several other research reports. Maxim Group set a $4.00 price target on shares of SCYNEXIS and gave the stock a buy rating in a research report on Wednesday, July 24th. Aegis initiated coverage on shares of SCYNEXIS in a research report on Wednesday, July 31st. They set a buy rating for the company. ValuEngine downgraded shares of SCYNEXIS from a buy rating to a hold rating in a research report on Saturday, May 18th. LADENBURG THALM/SH SH set a $6.00 price target on shares of SCYNEXIS and gave the stock a buy rating in a research report on Friday, May 24th. Finally, Zacks Investment Research downgraded shares of SCYNEXIS from a hold rating to a sell rating in a research report on Wednesday, May 22nd. One analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the stock. The company currently has a consensus rating of Buy and a consensus target price of $4.30.
SCYX opened at $1.04 on Monday. SCYNEXIS has a twelve month low of $0.35 and a twelve month high of $1.90. The company has a quick ratio of 4.99, a current ratio of 4.99 and a debt-to-equity ratio of 1.73. The company has a 50-day moving average price of $1.19 and a 200 day moving average price of $1.35. The company has a market cap of $59.61 million, a PE ratio of -2.12 and a beta of 2.31.
SCYNEXIS (NASDAQ:SCYX) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.02. SCYNEXIS had a negative net margin of 11,653.81% and a negative return on equity of 141.28%. The firm had revenue of $0.06 million during the quarter, compared to the consensus estimate of $0.06 million. As a group, sell-side analysts expect that SCYNEXIS will post -0.9 earnings per share for the current year.
A number of hedge funds and other institutional investors have recently made changes to their positions in SCYX. Two Sigma Investments LP purchased a new stake in SCYNEXIS during the 4th quarter valued at about $80,000. Deutsche Bank AG purchased a new stake in SCYNEXIS during the 4th quarter valued at about $121,000. Creative Planning grew its stake in SCYNEXIS by 9.3% during the 2nd quarter. Creative Planning now owns 139,000 shares of the company’s stock valued at $182,000 after acquiring an additional 11,824 shares in the last quarter. Bailard Inc. purchased a new stake in SCYNEXIS during the 1st quarter valued at about $196,000. Finally, Renaissance Technologies LLC grew its stake in SCYNEXIS by 86.1% during the 2nd quarter. Renaissance Technologies LLC now owns 475,315 shares of the company’s stock valued at $623,000 after acquiring an additional 219,900 shares in the last quarter. 30.71% of the stock is owned by institutional investors.
SCYNEXIS Company Profile
SCYNEXIS, Inc is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections.
Receive News & Ratings for SCYNEXIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS and related companies with MarketBeat.com's FREE daily email newsletter.